



## **MEMORANDUM**

**TO:** Hospital Administrators  
Hospital Pharmacists  
Pharmacists  
Infusion Sites  
Local Health Departments  
Primary Care Physicians  
Hospital Emergency Response Coordinators  
Regional Hospital Coordinating Centers

**FROM:** IDPH - Office of Preparedness and Response

**RE: Provider Survey & AstraZeneca EVUSHELD EUA, FAQ**

### **COVID-19 Antiviral Provider Survey**

IDPH has created a survey for providers to indicate if they would like to be considered to dispense EVUSHELD and, pending an EUA, Molnupiravir, Merck's oral COVID-19 therapeutic. HHS has indicated that these therapies will have a limited initial supply. Please, fill out the survey to indicate if your facility does or does not intend to provide these therapies.

## **PROVIDER COVID-19 ANTIVIRAL SURVEY**

### **AstraZeneca Emergency Use Authorization (EUA) for EVUSHELD**

The FDA has issued an EUA for AstraZeneca's EVUSHELD for emergency use as a pre-exposure prophylaxis for prevention of COVID-19 in adults and pediatric individuals (12 years of age and older weighting at least 40 kg) who are immunosuppressed or have contraindications to receiving the Covid 19 vaccine. See links below for EUA, FAQ, and Fact Sheet.

### **[EVUSHELD EUA](#)**

### **[EVUSHELD Frequently Asked Questions](#)**

### **[EVUSHELD Health Care Provider Fact Sheet](#)**

An EUA has not been issued at this time for Merck's Molnupiravir at this time. When more information becomes available, we will distribute.

**Supportive Resources:**

- [IDPH Monoclonal Antibody website](#)
- [IDPH Monoclonal Antibody Request Form \(smartsheet.com\)](#)  
(Must use Chrome, Firefox, Safari or Microsoft Edge)
- [Monoclonal Antibody Therapy Playbook](#)
- Amerisource Bergen support center: [C19therapies@amerisourcebergen.com](mailto:C19therapies@amerisourcebergen.com)
- [New Site \(smartsheet\)](#)  
(Must use Chrome, Firefox, Safari or Microsoft Edge)
- [mAb Matchmaker](#)  
(Must use Chrome, Firefox, Safari or Microsoft Edge)
- **IDPH Technical Assistance:**
  - **All COVID Therapeutic Questions:** [DPH.MABTherapy@illinois.gov](mailto:DPH.MABTherapy@illinois.gov)